Trial designs advance to overcome bitter pill of placebo effect.
- Published in:
- Nature Medicine, 2013, v. 19, n. 11, p. 1353, doi. 10.1038/nm1113-1353
- By:
- Publication type:
- Article
Works matching DE "ALKERMES Inc."
Results: 9
1
2
APPA CORPORATE MEMBERS.
- Published in:
- Perspectives (0821-1507), 2018, v. 42, n. 3, p. 16
- Publication type:
- Article
3
PsychRx.
- Published in:
- Psychiatry (1550-5952), 2010, v. 7, n. 5, p. 9
- Publication type:
- Article
4
ALKERMES ANNOUNCES POSITIVE RESULTS FROM TWO CLINICAL TRIALS OF ALKS 33.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 10, p. 9
- Publication type:
- Article
5
Psych Rx.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 4, p. 12
- By:
- Publication type:
- Article
6
Trial watch: Opioid receptor blocker shows promise in Phase II depression trial.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 6, p. 415, doi. 10.1038/nrd4028
- By:
- Publication type:
- Article
7
FDA actions in brief.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 213
- Publication type:
- Article
8
Product Update.
- Published in:
- Journal of Psychosocial Nursing & Mental Health Services, 2006, v. 44, n. 6, p. 8
- Publication type:
- Article
9
Alkermes, Elan in $960 million merger.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 7, p. 559, doi. 10.1038/nbt0711-559b
- By:
- Publication type:
- Article